


Metastatik Kolon Kanserinde Tedavi Seçenekleri

Dr. Deniz Tural
Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi
Tıbbi Onkoloji

Kolon Kanseri İnsidans ve Mortalite

Percent of New Cases by Age Group: Colon and Rectum Cancer



Colon and rectum cancer is most frequently diagnosed among people aged 65-74.

Median Age At Diagnosis

68

SEER 18 2009-2013, All Races, Both Sexes

Kolon Kanseri İnsidans ve Mortalite

Common Types of Cancer	Estimated New Cases 2016	Estimated Deaths 2016
1. Breast Cancer (Female)	246,660	40,450
2. Lung and Bronchus Cancer	224,390	158,080
3. Prostate Cancer	180,890	26,120
4. Colon and Rectum Cancer	134,490	49,190
5. Bladder Cancer	76,960	16,390
6. Melanoma of the Skin	76,380	10,130
7. Non-Hodgkin Lymphoma	72,580	20,150
8. Thyroid Cancer	64,300	1,980
9. Kidney and Renal Pelvis Cancer	62,700	14,240
10. Leukemia	60,140	24,400

Colon and rectum cancer represents 8.0% of all new cancer cases in the U.S.



In 2016, it is estimated that there will be 134,490 new cases of colon and rectum cancer and an estimated 49,190 people will die of this disease.


Kolon Kanseri İnsidans ve Mortalite

Estimated New Cases in 2016	134,490
-----------------------------	---------

% of All New Cancer Cases	8.0%
---------------------------	------

Estimated Deaths in 2016	49,190
--------------------------	--------

% of All Cancer Deaths	8.3%
------------------------	------



Percent Surviving 5 Years

65.1%

2006-2012

Number of New Cases and Deaths per 100,000: The number of new cases of colon and rectum cancer was 41.0 per 100,000 men and women per year. The number of deaths was 15.1 per 100,000 men and women per year. These rates are age-adjusted and based on 2009–2013 cases and deaths.


Lifetime Risk of Developing Cancer: Approximately 4.5 percent of men and women will be diagnosed with colon and rectum cancer at some point during their lifetime, based on 2010–2012 data.

Prevalence of This Cancer: In 2013, there were an estimated 1,177,556 people living with colon and rectum cancer in the United States.

Kolon Kanseri İnsidans ve Mortalite

New Cases, Deaths and 5-Year Relative Survival

[View Data Table](#)




Year	1975	1980	1985	1990	1995	2000	2004	2008
5-Year Relative Survival	48.6%	51.2%	58.1%	60.8%	59.7%	64.8%	65.7%	67.2%

SEER 9 Incidence & U.S. Mortality 1975-2013, All Races, Both Sexes. Rates are Age-Adjusted.


Kolon Kanseri İnsidans ve Mortalite

Percent of Cases & 5-Year Relative Survival by Stage at Diagnosis: Colon and Rectum Cancer

Percent of Cases by Stage




5-Year Relative Survival



SEER 18 2006-2012, All Races, Both Sexes by SEER Summary Stage 2000

Kolon Kanseri

Genetik ve Risk Faktörleri



Kolon Kanseri

Genetik ve Risk Faktörleri

Annual worldwide incidence of CRC is 1,023,152*:

- Lynch syndrome (LS) accounts for \approx 2-5% (20,460-51,160 cases).
- $<$ 1% (10,230 cases) constitute FAP.
- \approx 20% (204,630 cases) are familial (2 or more first-degree relatives with CRC).

*International Agency for Research on Cancer. Globocan 2002. Available at: <http://www-dep.iarc.fr/>.

Kolon Kanseri

Genetik ve Risk Faktörleri

Genetic Heterogeneity in HNPCC




HNPCC is associated with germline mutations in any one of at least five genes


Kolon Kanseri

Genetik ve Risk Faktörleri


Mismatch Repair Deficiency (MMR-D): Unique Biological Subgroup of Colon Cancer



IHC for MMR
protein status



PCR on tumor
DNA for MSI
(microsatellite
instability)




Imai and Yamamoto. Carcinogenesis 2008
Umetani, Annals of Surgical Oncology 2000
Rosen et al. Modern Pathology (2006) 19, 1414-1420

Kolon Kanseri

Genetik ve Risk Faktörleri

Mismatch Repair Deficiency (MMR-D): Unique Biological Subgroup of Colon Cancer




Thus, IHC for MMR proteins and PCR for MSI detect two manifestations of the same tumor biology:

- MMR-D is synonymous with MSI-H
- MMR-P is synonymous with MSI-L/MSS

Kolon Kanseri

Genetik ve Risk Faktörleri



Kolon Kanseri Tedavi

History of adjuvant therapy of colon cancer

- 5-FU/lev superior to surgery alone

- 5-FU/LV superior to surgery alone

- 5-FU/LV superior to 5-FU/lev
- 6- and 12-month treatment cycles equivalent
- Lev unnecessary
- High-dose and low-dose LV equivalent
- Monthly and weekly treatment equivalent

- LV5FU2 and monthly bolus equivalent

1990

1994

1998

2002

Moertel et al. *Ann Intern Med.* 1995;122:321.

Francini et al. *Gastroenterol.* 1994;106:899.

Wolmark et al. *Proc Am Soc Clin Oncol.* 1996;15:205. Abstract


O'Connell et al. *J Clin Oncol.* 1998;16:295.

Haller et al. *Proc Am Soc Clin Oncol.* 1998;17:256a. Abstract 982.

Andre et al. *Proc Am Soc Clin Oncol.* 2002. Abstract 529.

Kolon Kanseri Tedavi

Recurrence rate over time



Sargent et al., ASCO 2009

Kolon Kanserinde Adjuvan Tedavi Seçenekleri

Beyond 5-FU in the adjuvant setting

Completed studies:


- Capecitabine (X-ACT)
- Oxaliplatin (MOSAIC, NSABP C-07, XELOXA)
- Irinotecan (CALGB 89803, ACCORD-2, PETACC-3)
- Bevacizumab (NSABP C-08, AVANT)
- Cetuximab in KRAS wt CC (N0147, PETACC-8)

Ongoing studies:

- No novel agents tested at this point!
- IDEA collaboration tests 3 vs 6 months of oxaliplatin-based therapy

Kolon Kanserinde Adjuvan Tedavi Seçenekleri

X-ACT: Cape vs Mayo - 5-year DFS (median follow-up 6.8 years)



Test of non-inferiority $p < 0.0001$

Test of superiority $p = 0.0682$

ITT (intent-to-treat) population; NI = non-inferiority


ITT population

Twelves C, et al. Eur J Cancer Suppl

2007;5:1 (Abstract 1LB)

Kolon Kanserinde Adjuvan Tedavi Seçenekleri

MOSAIC: Study Design



Primary end-point: disease-free survival

Secondary end-points: safety, overall survival

Andre NEJM 2004

LV5FU2, Leucovorin 200 mg/m² iv over 2 hours followed by 5-fluorouracil 400 mg/m² bolus and 5-fluorouracil 600 mg/m² iv over 22 hours on Days 1 and 2, every 14 days; FOLFOX4, LV5FU2 + oxaliplatin 85 mg/m² iv over 2 hours on Day 1


Kolon Kanserinde Adjuvan Tedavi Seçenekleri

MOSAIC: Disease-free Survival - Final Update

Data cut-off: June 2006	5-year DFS %		HR [95% CI]	p-value
	FOLFOX4	LV5FU2		
ITT	73.3	67.4	0.80 [0.68–0.93]	0.003
Stage III	66.4	58.9	0.78 [0.65–0.93]	0.005
	Δ7.5			
Stage II	83.7	79.9	0.84 [0.62–1.14]	0.258
High-risk stage II n=576	82.1	74.9	0.74 [0.52–1.06]	—
	Δ7.2			
Low-risk stage II n=323	86.3	89.1	1.22 [0.66–2.26]	—

Kolon Kanserinde Adjuvan Tedavi Seçenekleri

MOSAIC: OS: Stage II and Stage III



Kolon Kanserinde Adjuvan Tedavi Seçenekleri


“High-risk” Stage II Colon Cancer in MOSAIC

- **Clinical, pathological parameters!**
 - T4 tumors
 - Obstruction/perforation
 - Lymphatic or vascular invasion
 - Undifferentiated histology
 - Less than 10 (12) Ln retrieved

Kolon Kanserinde Adjuvan Tedavi Seçenekleri

2009 Update of MOSAIC Trial

Prognostic factor (n)	Hazard ratio (95% CI)
Overall	
Sex	



No benefit in OS with FOLFOX vs 5-FU/LV for patients ≥ 65 yrs !

Metastatik Kolon Kanseri Tedavi

- ❑ Kolon kanseri tanısı alan hastaların %50-60 oranında metastaz gelişir
- ❑ Metastazın %80-90 unrezektable karaciğer metastazı şeklinde olur
- ❑ Sıklıkla metakron metastaz şeklinde, senkron metastaz %20-34 oluşturur, daha kötü prognoza sahip

Metastatik Kolon Kanseri Tedavi

NCCTG/Intergroup Trial N9741 Efficacy

	IFL	FOLFOX	p-value
OS	15.0 mo	19.5 mo	0.0001
TTP	6.9 mo	8.7 mo	0.0014
RR	31%	45%	0.002

Metastatik Kolon Kanserinde Tedavi Seçenekleri


Tournigand-Trial (N=220)

	FOLFOX → FOLFIRI (1 st line → 2 nd line) 111 → 69		FOLFIRI → FOLFOX (1 st line → 2 nd line) 109 → 81	
N pts	111	69	109	81
RR	54%	4%	56%	15%
Liver resection	21%		9%	
PFS (mos)	8.1	2.5	8.5	4.2
OS (mos)	20.6		21.5	


2nd line:
62%

2nd line:
74%

Metastatik Kolon Kanseri Tedavi



Metastatik Kolon Kanserinde Tedavi Seçenekleri




Metastatik Kolon Kanserinde Tedavi Seçenekleri

Phase III Trial IFL +/- Bevacizumab in MCRC: Efficacy

	IFL+ Placebo (n=411)	IFL+ Bevacizumab (n=402)	P Value
Median survival (mo)	15.6	20.3	0.00004
PFS (mo)	6.2	10.6	<0.00001
ORR (%)	35	45	0.0036
CR	2.2	3.7	
PR	32.5	41.2	
Duration of resp. (mo)	7.1	10.4	0.0014

Metastatik Kolon Kanserinde Tedavi Seçenekleri

Phase III Trial of IFL +/- Bevacizumab in MCRC: PFS



Metastatik Kolon Kanserinde Tedavi Seçenekleri

XELOX vs FOLFOX +/- Bevacizumab Roche NO16966 study design

Recruitment
June 2003 – May 2004

XELOX N=317
FOLFOX4 N=317

Initial 2-arm
open-label study
(N=634)

Recruitment
Feb 2004 – Feb 2005


XELOX + placebo N=350	XELOX + bevacizumab N=350
FOLFOX4 + placebo N=351	FOLFOX4 + bevacizumab N=350

Protocol amended to 2x2 placebo-
controlled design after bevacizumab
phase III data¹ became available
(N=1401)

¹Hurwitz H, et al. Proc ASCO 2003;22 (Abstract 3646)

Metastatik Kolon Kanserinde Tedavi Seçenekleri

NO16966 PFS Subgroup Analyses: On-Treatment Population




HR = 0.61 [97.5% CI 0.48–0.78]
 $P \leq .0001$

XELOX + placebo

VS

XELOX + Bev



HR = 0.65 [97.5% CI 0.50–0.84]
 $P = .0002$

FOLFOX4 +
placebo

VS

FOLFOX-4 +
Bev

Metastatik Kolon Kanserinde Tedavi Seçenekleri




Fig 2. Progression-free survival (intent to treat population). XELOX, capecitabine and oxaliplatin; FOLFOX-4, infused fluorouracil, folinic acid, and oxaliplatin; HR, hazard ratio.





Fig 3. Overall survival (intent to treat population). XELOX, capecitabine and oxaliplatin; FOLFOX-4, infused fluorouracil, folinic acid, and oxaliplatin; HR, hazard ratio.

Saltz LB, et al, JCO 2008

Metastatik Kolon Kanserinde Tedavi Seçenekleri

AVEX - Study design



- **Key inclusion criteria**


- ECOG PS 0–2
- Prior adjuvant chemotherapy allowed if completed >6 month before inclusion
- Not optimal candidates for a combination chemotherapy with irinotecan or oxaliplatin

- **Key exclusion criteria**

- Prior chemotherapy for mCRC or prior adjuvant anti-VEGF treatment
- Clinically significant cardiovascular disease
- Current or recent use of aspirin (>325 mg/day) or other NSAID
- Use of full-dose anticoagulants or thrombolytic agents

Metastatik Kolon Kanserinde Tedavi Seçenekleri


AVEX - PFS




Number at risk

Cape + BEV	140	121	99	80	68	55	41	28	23	16	13	9	8	3	2	2	2	2	1	0	0
Cape	140	109	82	56	38	25	13	9	6	4	4	2	1	1	1	1	1	1	1	1	0


Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri

Bevasizumab İdame Tedavi

Trial	Maintenance Regimen	medyan PFS, Mos	P değeri	medyan OS, Mos	P değeri
STOP and GO^[1]					
▪ Experimental	Bevasizumab+XELOX	8.3	0.002	20.2	
▪ Control	Bevasizumab+Xeloda	11		23.8	
MACRO^[2]					
▪ Experimental	CAPOX-B	10.4	.38	23.2	.65
▪ Control	Bevasizumab	9.7		19.99	
CAIRO-3^[3]					
▪ Experimental	CAPOX-B	11.7*	< .0001	21.6	.22 [†]
▪ Control	Observation	8.5*		18.1	
SAKK 41/06^[4]					
▪ Experimental	Bevasizumab	9.5	.021	25.1	.218
▪ Control	Observation	8.5		22.8	
AIO 0207^[5]					
▪ Experimental	FP + Bev/Bev	6.2/4.2	< .0001	23.8/26.2	.70
▪ Control	Observation	3.6		23.1	

1. Stop and Go Yalcın et.al. Oncology 2013 2. Diaz-Rubio E, ve ark. Oncologist. 2012;17:15-25. 3. Koopman M, ve ark. ASCO 2014. Abstract 3504. 4. Koeberle D, ve ark. ASCO 2013. Abstract 3503. 5. Arnold D, ve ark. ASCO 2014 Abstract 3503.

Metastatik Kolon Kanserinde Tedavi Seçenekleri

Bevacisumab -Metaanaliz

Hurwitz, Tebbutt, Kabbinavar et al.

1005

Table 1. Overview of clinical trials included in the analysis

Trial (ClinicalTrials.gov identifier)	Phase	Treatment arms included in the current analysis	Subjects in ITT population	Primary endpoint
First-line mCRC				
AVF2107 (NCT00109070) [1]	III	IFL plus bevacizumab 5 mg/kg	402	OS
		IFL plus placebo	411	
NO16966 (NCT00069095) [4]	III	FOLFOX or XELOX plus bevacizumab 5 or 7.5 mg/kg	699	PFS
		FOLFOX or XELOX plus placebo	701	
ARTIST (NCT00642577) [6]	III	mIFL plus bevacizumab 5 mg/kg	142	PFS, 6-month PFS rate
		mIFL	72	
AVF0780 [16]	II	5-FU/LV plus bevacizumab 5 mg/kg	35	TTP, confirmed response rate
		5-FU/LV plus placebo	36	
AVF2192 (NCT00109226) [2]	II	5-FU/LV plus bevacizumab 5 mg/kg	104	OS
		5-FU/LV plus placebo	105	
AGITG MAX (NCT00294359) [5]	III	Capecitabine plus bevacizumab 7.5 mg/kg with or without mitomycin	315	PFS
		Capecitabine	156	
Second-line mCRC				
E3200 (NCT00025337) [3]	III	FOLFOX plus bevacizumab 10 mg/kg	293	OS
		FOLFOX	292	

Abbreviations: 5-FU/LV, 5-fluorouracil and leucovorin; FOLFOX, infusional 5-FU/LV with oxaliplatin; IFL, bolus 5-FU/LV with irinotecan; ITT, intent-to-treat; mCRC, metastatic colorectal cancer; mIFL, modified infusional 5-FU/LV with irinotecan; OS, overall survival; PFS, progression-free survival; TTP, time to disease progression; XELOX, capecitabine with oxaliplatin.

Metastatik Kolon Kanserinde Tedavi Seçenekleri




Figure 1. Overall survival (OS) in the overall pooled population and in individual studies (first- and second-line trials of bevacizumab). (A): Kaplan-Meier estimate of OS for the overall pooled population. (B): Forest plot of OS by study.

Abbreviations: BV, bevacizumab; CI, confidence interval; CT, chemotherapy; HR, hazard ratio; OS, overall survival.

Metastatik Kolon Kanserinde Tedavi Seçenekleri




Figure 2. Progression-free survival (PFS) in the overall pooled population and in individual studies (first- and second-line trials of bevacizumab). **(A):** Kaplan-Meier estimate of PFS for the pooled population. **(B):** Forest plot of PFS by study.

Abbreviations: BV, bevacizumab; CI, confidence interval; CT, chemotherapy; HR, hazard ratio; PFS, progression-free survival.

Metastatik Kolon Kanserinde Tedavi Seçenekleri

1010

Bevacizumab Efficacy and Safety in mCRC: Pooled Analysis


Table 3. Subgroup analyses in the overall pooled population (first- and second-line trials of bevacizumab) and first-line pooled population

	Overall survival			Progression-free survival		
	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value
Overall pooled population (N = 3,763)	0.80	0.71–0.90	.0003	0.57	0.46–0.71	<.0001
Irinotecan regimen (n = 1,027)	0.71	0.61–0.83	<.0001	0.55	0.47–0.64	<.0001
Oxaliplatin regimen (n = 1,985)	0.87	0.79–0.96	.0037	0.77	0.70–0.85	<.0001
Monotherapy (n = 751)	0.86	0.72–1.02	.0773	0.56	0.48–0.67	<.0001
Doublets (n = 3,012)	0.82	0.76–0.89	<.0001	0.70	0.64–0.76	<.0001
Patients with liver metastases only (n = 1,240)	0.84	0.74–0.95	.0066	0.65	0.57–0.74	<.0001
Patients with extensive disease ^a (n = 1,279)	0.79	0.70–0.89	.0001	0.66	0.58–0.74	<.0001
Aged <65 yr (n = 2,269)	0.80	0.73–0.88	<.0001	0.68	0.62–0.75	<.0001
Aged ≥65 yr (n = 1,492)	0.87	0.77–0.97	.0156	0.66	0.59–0.75	<.0001
Aged ≥75 yr (n = 426)	0.76	0.62–0.94	.0118	0.55	0.44–0.70	<.0001
ECOG PS 0 (n = 2,038)	0.80	0.72–0.89	<.0001	0.67	0.61–0.74	<.0001
ECOG PS ≥1 (n = 1,719)	0.85	0.77–0.94	.0020	0.67	0.60–0.75	<.0001
KRAS wild-type patients (n = 364)	0.70	0.54–0.91	.0072	0.57	0.45–0.72	<.0001
KRAS mutant patients (n = 166)	0.85	0.60–1.22	.3837	0.54	0.38–0.76	.0004
Overall first-line population (n = 3,178)	0.81	0.70–0.93	.0034	0.58	0.46–0.73	<.0001
Irinotecan regimen (n = 1,027)	0.71	0.61–0.83	<.0001	0.55	0.47–0.64	<.0001
Oxaliplatin regimen (n = 1,400)	0.93	0.83–1.04	.1904	0.85	0.76–0.94	.0025
Monotherapy (n = 751)	0.86	0.72–1.02	.0773	0.56	0.48–0.67	<.0001
Doublet therapy (n = 2,427)	0.84	0.77–0.92	.0003	0.73	0.67–0.80	<.0001
Patients with liver metastases only (n = 1,095)	0.87	0.76–1.00	.0449	0.67	0.59–0.77	<.0001
Patients with extensive disease ^a (n = 1,049)	0.79	0.69–0.90	.0004	0.67	0.59–0.77	<.0001
Aged <65 yr (n = 1,902)	0.82	0.74–0.91	.0002	0.70	0.63–0.78	<.0001
Aged ≥65 yr (n = 1,275)	0.88	0.78–1.00	.0524	0.68	0.60–0.78	<.0001
Aged ≥75 yr (n = 357)	0.80	0.63–1.00	.0533	0.57	0.45–0.74	<.0001
ECOG PS 0 (n = 1,749)	0.81	0.73–0.91	.0004	0.69	0.62–0.77	<.0001
ECOG PS ≥1 (n = 1,424)	0.87	0.78–0.98	.0207	0.69	0.61–0.78	<.0001
KRAS wild-type patients (n = 364)	0.70	0.54–0.91	.0072	0.57	0.45–0.72	<.0001
KRAS mutant patients (n = 166)	0.85	0.60–1.22	.3837	0.54	0.38–0.76	.0004

^aPatients with metastatic disease in at least one site other than the liver or the lung.


Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.

Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri

ML18147 study design (Phase III)



Primary endpoint

Secondary endpoints included

Stratification factors

- Overall survival (OS) from randomization
- Progression-free survival (PFS)
- Best overall response rate
- Safety
- First-line CT (oxaliplatin-based, irinotecan-based)
- First-line PFS (≤ 9 months, > 9 months)
- Time from last BEV dose (≤ 42 days, > 42 days)
- ECOG PS at baseline (0/1, 2)

Metastatik Kolon Kanserinde Tedavi Seçenekleri

Abstract

Send to

Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borq C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators.

Collaborators (230)

Abstract

BACKGROUND: Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and bevacizumab-naïve second-line metastatic colorectal cancer. We assessed continued use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment.

METHODS: In an open-label, phase 3 study in 220 centres in Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, the Netherlands, Norway, Portugal, Saudi Arabia, Spain, Sweden, and Switzerland, patients (aged ≥ 18 years) with unresectable, histologically confirmed metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy were randomly assigned in a 1:1 ratio to second-line chemotherapy with or without bevacizumab 2.5 mg/kg per week equivalent (either 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, intravenously). The choice between oxaliplatin-based or irinotecan-based second-line chemotherapy depended on the first-line regimen (switch of chemotherapy). A combination of a permuted block design and the Pocock and Simon minimisation algorithm was used for the randomisation. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number [NCT00700102](#).

FINDINGS: Between Feb 1, 2006, and June 9, 2010, 409 (50%) patients were assigned to bevacizumab plus chemotherapy and 411 (50%) to chemotherapy alone. Median follow-up was 11.1 months (IQR 6.4-15.6) in the bevacizumab plus chemotherapy group and 9.6 months (5.4-13.9) in the chemotherapy alone group. Median overall survival was 11.2 months (95% CI 10.4-12.2) for bevacizumab plus chemotherapy and 9.8 months (8.9-10.7) for chemotherapy alone (hazard ratio 0.81, 95% CI 0.69-0.94; unstratified log-rank test $p=0.0062$). Grade 3-5 bleeding or haemorrhage (eight [2%] vs one [$<1\%$]), gastrointestinal perforation (seven [2%] vs three [$<1\%$]), and venous thromboembolisms (19 [5%] vs 12 [3%]) were more common in the bevacizumab plus chemotherapy group than in the chemotherapy alone group. The most frequently reported grade 3-5 adverse events were neutropenia (65 [16%] in the bevacizumab and chemotherapy group vs 52 [13%] in the chemotherapy alone group), diarrhoea (40 [10%] vs 34 [8%], respectively), and asthenia (23 [6%] vs 17 [4%], respectively). Treatment-related deaths were reported for four patients in the bevacizumab plus chemotherapy group and three in the chemotherapy alone group.

INTERPRETATION: Maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond disease progression has clinical benefits in patients with metastatic colorectal cancer. This approach is also being investigated in other tumour types, including metastatic breast and non-small cell lung cancers.

Full text links



Save items

Add to Favorites

Cited by 3 systematic reviews

Review The role of biological therapy in metastatic colorectal cancer [\[Br J Cancer. 2014\]](#)

Review Efficacy of adding bevacizumab in the first-line chemoth [\[Gastroenterol Res Pract. 2014\]](#)

Review An updated meta-analysis of fatal adverse events caused by beva [\[PLoS One. 2014\]](#)

Similar articles

Bevacizumab plus chemotherapy versus chemotherapy alone as sec [\[Lancet Oncol. 2014\]](#)

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 an [\[Lancet Oncol. 2013\]](#)

Bevacizumab plus capecitabine versus capecitabine alone in elderly [\[Lancet Oncol. 2013\]](#)

Review Bevacizumab in combination with fluoropyrimidine-b [\[Health Technol Assess. 2010\]](#)


Review Systematic review and economic evaluation of beva [\[Health Technol Assess. 2007\]](#)

See reviews...

See all

Metastatik Kolon Kanserinde Tedavi Seçenekleri

EFC10262: VELOUR Phase III Trial 2nd-Line FOLFIRI +/- VEGF-TRAP (Aflibercept)




30% of patients had prior BEV

Metastatik Kolon Kanserinde Tedavi Seçenekleri

VELOUR Study


- Overall results

- Adding aflibercept to FOLFIRI in mCRC patients previously treated with an oxaliplatin-based regimen resulted in significant OS and PFS benefits



Number at Risk

	0	3	6	9	12	15	18	21	24	27	30	33	36	39
Placebo	614	573	485	401	286	193	131	87	51	31	14			
AFL	612	566	489	416	311	216	148	104	75	49	33			




Number at Risk

	0	3	6	9	12	15	18	21	24	27	30
Placebo	614	355	171	94	46	24	9				
AFL	612	420	247	99	43	17	7				

Metastatik Kolon Kanserinde Tedavi Seçenekleri

I4T-MC-JVBB Phase III Trial 2nd-Line FOLFIRI +/- Ramucirumab



Stratification factors:

- Region
- KRAS status
- First-line TTP (< or > 6 mos)

Primary EP: OS


Metastatik Kolon Kanserinde Tedavi Seçenekleri

Comparison of Phase III Trials

Agent	Bevacizumab		Aflibercept		Ramucirumab	
Study	TML		VELOUR		RAISE	
1 st -Line Tx	Chemo+BEV		FP-Oxali+/- BEV		FP-Oxali+BEV	
	Ctx-BEV	Ctx	FOLFIRI + AFL	FOLFIRI + PL	FOLFIRI + RAM	FOLFIRI + PL
N pts	409	410	612	614	536	536
mOS (mos)	11.2	9.8	13.5	12.1	13.3	11.7
	HR 0.81 p=0.0062		HR 0.82 p=0.0032		HR 0.84 p=0.022	
mPFS (mos)	5.7	4.1	6.9	4.7	5.7	4.5
	HR 0.68 p<0.0001		HR 0.76 p=0.00007		HR 0.79 p=0.0005	
RR (%)	5.4	3.9	19.8	11.1	13.4	12.5

Bennouna et al., Lancet Oncol 2012
 van Cutsem et al., JCO 2012
 Tabernero et al., ASCO GI 2015; Abstract 512


Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri

KRAS as Biomarker for Panitumumab Response in Metastatic CRC

- PFS log HR significantly different depending on K-ras status ($P < .0001$)
- Percentage decrease in target lesion greater in patients with wild-type KRAS receiving panitumumab



Metastatik Kolon Kanserinde Tedavi Seçenekleri

NCIC CTG CO.17: Randomized Phase III Trial in mCRC Cetuximab vs BSC (no cross-over)

	KRAS mut		KRAS wild-type		All patients	
	BSC n=83	Cetux n=81	BSC n=113	Cetux n=117	BSC n=285	Cetux n=287
RR	0%	1.2%	0%	12.8%	0%	6.6%
PFS (mos)	1.8	1.8	1.9	3.8	1.8	1.9
			<0.0001		<0.0001	
OS (mos)	4.6	4.5	4.8	9.5	4.6	6.1
			<0.0001		0.0046	

Metastatik Kolon Kanserinde Tedavi Seçenekleri

CRYSTAL Study (1st Line)



- Primary Endpoint: PFS (independent review)
- Secondary Endpoints: RR, DCR, OS, Safety, QoL
- Sample Size: 1217 patients randomized, ITT: 1198 pts

Metastatik Kolon Kanserinde Tedavi Seçenekleri

CRYSTAL ÇALIŞMASI





Figure 1. Kaplan-Meier Estimates of Progression-free and Overall Survival in the Primary Analysis Population and the Wild-Type-KRAS Population, According to Treatment Group.

Panel A shows progression-free survival among the 1198 patients in the primary analysis population. The hazard ratio for the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% CI, 0.72 to 0.99; $P=0.048$ by a stratified log-rank test). Median progression-free survival time in the cetuximab-FOLFIRI group was 8.9 months (95% CI, 8.0 to 9.5), as compared with 8.0 months (95% CI, 7.6 to 9.0) in the FOLFIRI group. Panel B shows overall survival among the 1198 patients in the primary analysis population. The hazard ratio for death in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.93 (95% CI, 0.81 to 1.07; $P=0.31$ by a stratified log-rank test). The median overall survival in the cetuximab-FOLFIRI group was 19.9 months (95% CI, 18.5 to 21.3), as compared with 18.6 months (95% CI, 16.6 to 19.8) in the FOLFIRI group. Panel C shows progression-free survival among the 348 patients with wild-type-KRAS tumors. The hazard ratio for progression in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.68 (95% CI, 0.50 to 0.94; $P=0.02$). The median progression-free survival in the cetuximab-FOLFIRI group was 9.9 months (95% CI, 8.7 to 14.6), as compared with 8.7 months (95% CI, 7.4 to 9.9) in the FOLFIRI group. Panel D shows overall survival among the 348 patients with wild-type-KRAS tumors. The hazard ratio for death in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.84 (95% CI, 0.64 to 1.11). The median overall survival in the cetuximab-FOLFIRI group was 24.9 months (95% CI, 22.2 to 27.8), as compared with 21.0 months (95% CI, 19.2 to 25.7) in the FOLFIRI group.

Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri

Outcomes of Phase III First Line Trials with EGFR mAbs


Trial	Fluoro-pyrimidine	Iri or Ox	EGFR mAb	Significant improvement in		
				RR	PFS	OS
CRYSTAL	Inf + bolus 5-FU	Iri	C	+	+	+
PRIME	Inf + bolus 5-FU	Ox	P	+	+	(+)
COIN	Inf + bolus 5-FU	Ox	C	+	+	-
	Capecitabine	Ox	C	-	-	-
NORDIC	Bolus 5-FU	Ox	C	-	-	-

Table 1 Clinical trials of targeted agents in combination with chemotherapy as first-line treatments for metastatic colorectal cancer

Ref.	Year	Population	Patient number	Regimen	Median PFS (mo)	P ¹	Median OS (mo)	P ¹	Response rate (%)	P ¹
CRYSTAL ⁽¹⁹⁾	2009	All	599	FOLFIRI	8.0	0.048	18.6	0.31	38.7	0.0038
			599	FOLFIRI + Cetuximab	8.9		19.9		46.9	
		KRAS WT subgroup	350	FOLFIRI	8.4	0.0012	20	0.0093	39.7	< 0.001
			316	FOLFIRI + Cetuximab	9.9		23.5		57.3	
OPUS ⁽²¹⁾	2009	All	183	FOLFIRI	7.7	0.26	16.7	0.75	36.1	0.35
			214	FOLFIRI + Cetuximab	7.4		16.2		31.3	
		KRAS WT subgroup	168	FOLFOX4	7.2	0.62	18	0.91	36	0.064
			169	FOLFOX4 + Cetuximab	7.2		18.3		46	
COIN ⁽²⁰⁾	2011	KRAS WT group	97	FOLFOX4	7.2	0.0064	18.5	0.39	34	0.0027
			82	FOLFOX4 + Cetuximab	8.3		22.8		57	
		KRAS MT subgroup	59	FOLFOX4	8.6	0.0153	17.5	0.2	53	0.029
			77	FOLFOX4 + Cetuximab	5.5		13.4		34	
NORDIC-VII ⁽²¹⁾	2012	All	367	FOLFOX/XELOX	8.6	0.60	17.9	0.68	57	0.049
			362	FOLFOX/XELOX + Cetuximab	8.6		17		64	
		KRAS WT group	127	FOLFOX	9.2	0.056	-	-	-	-
			117	FOLFOX + Cetuximab	9.0		-	-	-	-
CALGB/SWOG ⁽²²⁾	2014	KRAS WT group	240	XELOX	8.0	0.56	-	-	-	-
			245	XELOX + Cetuximab	8.4		-	-	-	-
		KRAS MT group	268	FOLFOX/XELOX	-	-	14.8	0.8	-	-
			297	FOLFOX/XELOX + Cetuximab	-	-	13.6		-	-
PRIME ⁽²¹⁾	2010	All	185	Nordic FLOX (control group)	7.9	-	20.4	-	41	-
			194	FLOX + Cetuximab	8.3	0.31	19.7	0.67	49	0.15
		KRAS WT subgroup	187	intermittent FLOX + Cetuximab	7.3	NA	20.3	0.79	47	NA
			97	Nordic FLOX (control group)	8.7	-	22	-	47	-
Hyman <i>et al</i> ⁽²⁷⁾	2015	BRAF V600 group	109	intermittent FLOX + Cetuximab	7.5	NA	21.4	0.66	51	NA
			58	Nordic FLOX (control group)	7.8	-	20.4	-	40	-
		KRAS MT subgroup	72	FLOX + Cetuximab	9.2	0.07	21.1	0.89	49	0.31
			65	intermittent FLOX + Cetuximab	7.2	NA	20.5	0.84	42	NA
Reidy <i>et al</i> ⁽²¹⁾	2010	All	578	FOLFIRI or mFOLFOX6 + Cetuximab	10.45	NA	29.93	0.34	-	-
			559	FOLFIRI or mFOLFOX6 + Bevacizumab	10.84		29.04		-	-
80405 (study is ongoing)	2010	KRAS WT group	331	FOLFOX4	8.0	0.02	19.7	0.072	48	0.068
			325	FOLFOX4 + Paritumumab	9.6		23.9		55	
		KRAS MT group	219	FOLFOX4	8.8	0.02	19.3	0.068	40	-
			221	FOLFOX4 + Paritumumab	7.3		15.5		40	-
CALGB/SWOG ⁽²²⁾	2014	KRAS WT group	578	FOLFIRI or mFOLFOX6 + Cetuximab	10.45	NA	29.93	0.34	-	-
			559	FOLFIRI or mFOLFOX6 + Bevacizumab	10.84		29.04		-	-
80405 (study is ongoing)	2010	KRAS WT group	331	FOLFOX4	8.0	0.02	19.7	0.072	48	0.068
			325	FOLFOX4 + Paritumumab	9.6		23.9		55	
80405 (study is ongoing)	2010	KRAS MT group	219	FOLFOX4	8.8	0.02	19.3	0.068	40	-
			221	FOLFOX4 + Paritumumab	7.3		15.5		40	-
80405 (study is ongoing)	2010	All	10	Vemurafenib	4.5	-	9.3	-	0	-
			27	Vemurafenib + Cetuximab	3.7		7.1		4	-
80405 (study is ongoing)	2010	All	23	IMC-A12 (anti-IGF-1R antibody)	5.9	-	5.2	-	0	-
			21	IMC-A12 (anti-IGF-1R antibody) + Cetuximab	6.1		4.5		5	-
80405 (study is ongoing)	2010	KRAS WT group	20	IMC-A12 (anti-IGF-1R antibody) + Cetuximab	9.4		10.9		0	-


¹95%CI. PFS: Progression-free survival; OS: Overall survival; All: All patients group; WT: Wild type; MT: Mutant type; NA: Not available; KRAS: KRAS exon 2, codons 12 and 13; FOLFIRI: Irinotecan, fluorouracil, and leucovorin; FOLFOX: Fluorouracil, leucovorin, and oxaliplatin; XELOX: Capecitabine and oxaliplatin; FLOX: Fluorouracil, leucovorin, and oxaliplatin.

Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri


Progression-free survival in (A) wild-type (WT) KRAS exon 2 intent-to-treat group and (B) extended WT RAS subgroup.



Lee S. Schwartzberg et al. JCO 2014;32:2240-2247

Metastatik Kolon Kanserinde Tedavi Seçenekleri



Overall survival in (A) wild-type (WT) KRAS exon 2 intent-to-treat group and (B) extended WT RAS subgroup.



Lee S. Schwartzberg et al. JCO 2014;32:2240-2247

Metastatik Kolon Kanserinde Tedavi Seçenekleri

Mutations beyond KRAS codon 12/13




NT=not tested

17% additional mutations in KRAS and NRAS !

Douillard et al., NEJM 2013

Metastatik Kolon Kanserinde Tedavi Seçenekleri

FIRE-3 Phase III study design



- Primary objective: Overall response rate (ORR) (inv assessed)
- Designed to detect a difference of 12% in ORR induced by FOLFIRI + cetuximab (62%) as compared to FOLFIRI + bevacizumab (50%)
- 284 evaluable patients per arm needed to achieve 80% power for an one-sided Fisher's exact test at an alpha level of 2.5%

Metastatik Kolon Kanserinde Tedavi Seçenekleri

FIRE-3 ORR Primary Endpoint


ORR	FOLFIRI + Cetuximab		FOLFIRI + Bevacizumab		Odds ratio	p
	%	95%-CI	%	95%-CI		
ITT population (N= 592)	62.0	56.2 – 67.5	58.0	52.1 – 63.7	1.18 0.85-1.64	0.183
Assessable for response (N= 526)	72.2	66.2 – 77.6	63.1	57.1 – 68.9	1.52 1.05-2.19	0.017

p = Fisher's exact test (one-sided)

Heinemann et al., ASCO 2013

Metastatik Kolon Kanserinde Tedavi Seçenekleri

FIRE-3 PFS



Heinemann et al., ASCO 2013

Metastatik Kolon Kanserinde Tedavi Seçenekleri


FIRE-3 Overall survival




number	297	218	111	60	29	9
at risk	295	214	111	47	18	2

Heinemann et al., ASCO 2013

Metastatik Kolon Kanserinde Tedavi Seçenekleri




Metastatik Kolon Kanserinde Tedavi Seçenekleri



Metastatik Kolon Kanserinde Tedavi Seçenekleri


CALGB/SWOG 80405: Overall Survival



Metastatik Kolon Kanserinde Tedavi Seçenekleri



BRAF Mutations in CRC

- BRAF is primary effector of RAS signaling
- BRAF mutations:
 - Occur most frequently in exon 15 (V600E)
 - Found in 4%-14% of patients with CRC
 - Mutually exclusive with RAS mutations



Metastatik Kolon Kanserinde Tedavi Seçenekleri

PETACC-3: Survival after relapse according to BRAF mutation status



Roth, A. D. et al. JCO 2010

Metastatik Kolon Kanserinde Tedavi Seçenekleri

GONO ÇALIŞMASI

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest



This Article

JCO May 1, 2007 vol. 25 no. 13
1670-1676

[Abstract](#) [Free](#)
[Full Text](#)
[PDF](#)

Table 4.

Objective Responses


Response	%	
	FOLFIRI (n = 122)	FOLFOXIRI (n = 122)
Investigators assessment		
Complete	6	8
Partial	35	58
Complete + partial	41*	66*
95% CI	0.32 to 0.50	0.56 to 0.74
Stable disease	33	21
Progression	24†	11†
Not assessable	2	2
Externally reviewed		
Complete	6	7
Partial	28	53
Complete + partial	34‡	60‡
95% CI	0.25 to 0.43	0.51 to 0.68
Stable disease	34	21
Progression	24†	11†
Not reviewed	8	8

- Abbreviations: FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOXIRI, fluorouracil, leucovorin, oxaliplatin, and irinotecan.
- †* P = .0002.

Metastatik Kolon Kanserinde Tedavi Seçenekleri

GONO ÇALIŞMASI


Kaplan-Meier estimates of (A) progression-free survival and (B) overall survival.



Metastatik Kolon Kanserinde Tedavi Seçenekleri


TRIBE ÇALIŞMASI

A Progression-free Survival



No. at Risk	0	6	12	18	24	30	36	42	48	54
FOLFIRI plus bevacizumab	256	203	94	46	26	14	7	3	0	0
FOLFOXIRI plus bevacizumab	252	208	125	74	35	21	11	5	2	1

B Overall Survival



No. at Risk	0	6	12	18	24	30	36	42	48	54
FOLFIRI plus bevacizumab	256	233	216	172	109	69	36	15	5	0
FOLFOXIRI plus bevacizumab	252	234	205	175	119	70	35	15	4	0

Figure 2. Kaplan–Meier Estimates of Progression-free and Overall Survival, According to Treatment Group.

Median progression-free survival was 9.7 months in the group receiving FOLFIRI plus bevacizumab (control group) and 12.1 months in the group receiving FOLFOXIRI plus bevacizumab (experimental group). Median overall survival was 25.8 months in the control group and 31.0 months in the experimental group.

Metastatik KOLON Kanserinde Tedavi Seçenekleri

TRIBE ÇALIŞMASI




Figure 3. Forest Plot of the Treatment Effect on Progression-free Survival in Subgroup Analyses.

The size of the squares is proportional to the size of the corresponding subgroup. Control denotes FOLFIRI plus bevacizumab, ECOG Eastern Cooperative Oncology Group, and experimental FOLFOXIRI plus bevacizumab.

R0
Rezeksiyon;
%15 vs. %12



Metastatik Kolon Kanserinde Tedavi Seçenekleri

Hangi Hasta Grubunda FOLFORİNOX+/-Bevacizumab

- ❑ Genel durumu iyi, ek hastalığı olmayan, genç hasta popülasyonunda
 - Sınırdaki rezektabel karaciğer metastazı varsa
 - BRAF mutant hastalar

Metastatik Kolon Kanserinde Tedavi Seçenekleri

Regorafenib (BAY 73-4506), an Oral Multikinase Inhibitor Targeting Multiple Tumor Pathways



Biochemical Activity	Regorafenib IC ₅₀ mean \pm SD nmol/l (n)
VEGFR1	13 \pm 0.4 (2)
Murine VEGFR2	4.2 \pm 1.6 (10)
Murine VEGFR3	46 \pm 10 (4)
TIE2	311 \pm 46 (4)
PDGFR- β	22 \pm 3 (2)
FGFR1	202 \pm 18 (6)
KIT	7 \pm 2 (4)
RET	1.5 \pm 0.7 (2)
RAF-1	2.5 \pm 0.6 (4)
B-RAF	28 \pm 10 (6)
B-RAF ^{V600E}	19 \pm 6 (6)


Wilhelm SM, et al. *Int J Cancer*. 2011;129(1):245-255.

Mross K, et al. *Clin Cancer Res*. 2012;18(9):2658-2667.

Strumberg D, et al. *Expert Opin Invest Drugs*. 2012;21(6):879-889.

Metastatik Kolon Kanserinde Tedavi Seçenekleri



Progression-free survival (secondary endpoint)



Metastatik Kolon Kanserinde Tedavi Seçenekleri

TAS-102

A NOVEL ANTI-METABOLITE COMBINATION
("Teaching an old dog new tricks")




CHARLES HEIDELBERGER

- TRI-FLUORO-THYMIDINE
 - A fluoropyrimidine nucleoside
- Synthesized in 1964
- $T_{1/2} = 12$ minutes
- TF-MP inhibits TS
- TF-TP incorporated into DNA
- Active in 5FU resistant cell lines
- Extensive first pass hepatic metabolism by Thymidine Phosphorylase
- Combined with TPI (Thymidine Phosphorylase Inhibitor, tipiracil)
- Effective oral dosing, BID

Metastatik Kolon Kanserinde Tedavi Seçenekleri


Global Randomized Phase III study RECURSE: Refractory Colorectal Cancer Study (NCT01607957)



- Treatment continuation until progression, intolerant toxicity or patient refusal
- Multicenter, randomized, double-blind, placebo-controlled, phase III
 - Stratification: *KRAS* status, time from diagnosis of metastatic disease, geographical region
- Sites: 13 countries, 114 sites
- Enrollment: June 2012 to October 2013

Metastatik Kolon Kanserinde Tedavi Seçenekleri


Overall Survival



N at Risk:		0	3	6	9	12	15	18
TAS-102	534	459	294	137	64	23	7	
Placebo	266	198	107	47	24	9	3	


Metastatik Kolon Kanserinde Tedavi Seçenekleri

Time to ECOG PS \geq 2 (Intent-to-treat population)



Metastatik Kolon Kanserinde Tedavi Seçenekleri

Key Subgroup Analysis of OS



*Not prespecified subgroup

Metastatik Kolon Kanserinde Tedavi Seçenekleri

TAS-102 Toxicity

- Mainly Hematologic (Grade 3)

	Grade 3 (%)	Grade 4 (%)
Leukopenia	19	3
Neutropenia	27	11
Anemia	18	-
Thrombopenia	4.5	0.5

- Minimal Non-hematologic toxicity

Table 1. Demographic and Baseline Characteristics of the Patients.*

Characteristic	Mismatch Repair-Deficient Colorectal Cancer (N=11)	Mismatch Repair-Proficient Colorectal Cancer (N=21)	Mismatch Repair-Deficient Noncolorectal Cancer (N=9)	P Value†
Median age (range) — yr	46 (24–65)	61 (32–79)	57 (34–92)	0.02
Sex — no. (%)				0.72
Female	5 (45)	8 (38)	4 (44)	
Male	6 (55)	13 (62)	5 (56)	
Race — no. (%)‡				0.66
White	8 (73)	17 (81)	8 (89)	
Black	1 (9)	3 (14)	0	
Other	2 (18)	1 (5)	1 (11)	
ECOG performance status — no. (%)§				0.07
0	0	6 (29)	2 (22)	
1	11 (100)	15 (71)	7 (78)	
Cancer type — no. (%)				>0.99
Colon	9 (82)	18 (86)	0	
Rectal	2 (18)	3 (14)	0	
Ampullary or cholangiocarcinoma	0	NA	4 (44)	
Endometrial	0	NA	2 (22)	
Small bowel	0	NA	2 (22)	
Gastric	0	NA	1 (11)	
Histologic grade — no. (%)				0.20
Well or moderately differentiated	7 (64)	18 (86)	4 (44)	
Poorly differentiated	4 (36)	3 (14)	3 (33)	
Other	0	0	2 (22)	
Stage IV cancer — no. (%)	11 (100)	21 (100)	9 (100)	>0.99
Liver metastases — no. (%)	6 (55)	11 (52)	6 (67)	>0.99
Median time since initial diagnosis (range) — mo	31 (6–95)	58 (27–192)	23 (2–105)	0.07
Previous therapies — no. (%)				0.89
1	0	0	1 (11)	
2	3 (27)	4 (19)	5 (56)	
3	3 (27)	5 (24)	1 (11)	
>4	5 (45)	12 (57)	2 (22)	
Detected germline mutation or known Lynch syndrome — no. (%)				<0.001
Yes	9 (82)	0	4 (44)	
No	2 (18)	21 (100)	4 (44)	
Unknown	0	0	1 (11)	
BRAF wild type — no. (%)				0.64
Yes	8 (73)	11 (52)	4 (44)	
No	0	1 (5)	0	
Unknown	3 (27)	9 (43)	5 (56)	
KRAS wild type — no. (%)				0.72
Yes	6 (55)	13 (62)	4 (44)	
No	5 (45)	8 (38)	1 (11)	
Unknown	0	0	4 (44)	

* NA denotes not applicable.

† P values are for the comparison between the cohort with mismatch repair-deficient colorectal cancer and the cohort with mismatch repair-proficient colorectal cancer.

‡ Race was self-reported.

§ Eastern Cooperative Oncology Group (ECOG) performance status is a measure of a patient's ability to perform activities of daily living; values range from 0 to 5, with higher scores indicating greater impairment.

Metastatik Kolon Kanserinde Tedavi Seçenekleri

PD-1 BLOCKADE IN MISMATCH-REPAIR DEFICIENCY

Table 2. Objective Responses According to RECIST Criteria.

Type of Response	Mismatch Repair–Deficient Colorectal Cancer (N=10)	Mismatch Repair–Proficient Colorectal Cancer (N=18)	Mismatch Repair–Deficient Noncolorectal Cancer (N=7)
Complete response — no. (%)	0	0	1 (14)*
Partial response — no. (%)	4 (40)	0	4 (57)†
Stable disease at week 12 — no. (%)	5 (50)	2 (11)	0
Progressive disease — no. (%)	1 (10)	11 (61)	2 (29)
Could not be evaluated — no. (%)‡	0	5 (28)	0
Objective response rate (95% CI) — %	40 (12–74)	0 (0–19)	71 (29–96)
Disease control rate (95% CI) — %§	90 (55–100)	11 (1–35)	71 (29–96)
Median duration of response — wk	Not reached	NA¶	Not reached
Median time to response (range) — wk	28 (13–35)	NA¶	12 (10–13)

* The patient had a partial response at 12 weeks, which then became a complete response at 20 weeks.

† One patient had a partial response at 12 weeks.


‡ Patients could not be evaluated if they did not undergo a scan at 12 weeks because of clinical progression.

§ The rate of disease control was defined as the percentage of patients who had a complete response, partial response, or stable disease for 12 weeks or more.

¶ The median time to response was not applicable (NA) because no responses were observed among patients with mismatch repair–proficient colorectal cancer.

Metastatik Kolon Kanserinde Tedavi Seçenekleri

CONTINUUM OF CARE - CHEMOTHERAPY FOR ADVANCED OR METASTATIC DISEASE:¹ (PAGE 1 of 9)



Additional options on [COL-C 2 of 9](#) through [COL-C 3 of 9](#)
For patients not appropriate for intensive therapy, see [COL-C 4 of 9](#)

*TAS-102

[See footnotes on COL-C 5 of 9](#)

Metastatik Kolon Kanserinde Tedavi Seçenekleri




National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2016 Colon Cancer

[NCCN Guidelines Index](#)
[Colon Cancer Table of Contents](#)
[Discussion](#)


CONTINUUM OF CARE - CHEMOTHERAPY FOR ADVANCED OR METASTATIC DISEASE:¹ (PAGE 2 of 9)



Additional options on [COL-C 1 of 9](#) through [COL-C 3 of 9](#)
For patients not appropriate for intensive therapy, see [COL-C 4 of 9](#)

Metastatik Kolon Kanserinde Tedavi Seçenekleri

CONTINUUM OF CARE - CHEMOTHERAPY FOR ADVANCED OR METASTATIC DISEASE:¹ (PAGE 3 of 9)



Additional options on [COL-C 1 of 9](#) through [COL-C 2 of 9](#)
For patients not appropriate for intensive therapy, see [COL-C 4 of 9](#)

Metastatik Kolon Kanserinde Tedavi Seçenekleri




National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2016
Colon Cancer

[NCCN Guidelines Index](#)
[Colon Cancer Table of Contents](#)
[Discussion](#)

CONTINUUM OF CARE - CHEMOTHERAPY FOR ADVANCED OR METASTATIC DISEASE:¹ (PAGE 4 of 9)



Metastatik Kolon Kanserinde Tedavi Seçenekleri

ESMO TEDAVİ REHBERİ

